Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo

Figure 2 Clostridioidesdifficile infection challenge mouse model studies. Study 1: The effects of fresh (vegetative) ADS024 culture vs ADS024 spore preparations on the clinical manifestations of Clostridioides difficile infection (CDI) over 10 d. ADS024 was delivered to the mice (n = 15 per group) as resuspended spore suspensions [in phosphate-buffered saline (PBS)] or as a freshly prepared daily culture (ADS024 bacteria resuspended in PBS) 24 h prior to C. difficile. A: The weight loss comparison between mice receiving vegetative vs spore ADS024 relative to the infection (vehicle-dosed) controls; B: The adverse health effects comparison in surviving animals among the 3 groups (control, vegetative ADS024, and spore ADS024); C: The daily score of adverse health observations among the 3 groups was determined as shown in Supplementary Table 1. Study 2: The effects of single daily (QD) doses vs 3 times daily (TID) administration with fresh ADS024 in the mice (n = 10 per group) over the course of 10 d; D: The weight loss comparison among the 4 groups (vancomycin, untreated, QD, and TID); E: The adverse health effects comparison in the surviving animals among the 4 groups; F: The daily score of adverse health observations among the 4 groups was determined as shown in Supplementary Table 1.